Genmab, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $36.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Genmab’s strong financial performance and promising pipeline developments. The company reported a higher-than-expected net income for the second quarter of 2025, with significant revenue contributions from DARZALEX royalties. This financial strength is complemented by a robust cash position, which positions Genmab well to navigate challenges in the biotech sector.
Additionally, upcoming catalysts such as potential FDA approvals and updates on key clinical trials contribute to the positive outlook. The anticipated approval of the epcoritamab and rituximab combination for follicular lymphoma, along with other pipeline advancements, underscores Genmab’s potential for growth. These elements, combined with a solid track record in the multiple myeloma market, support the Buy rating and the increased price target of $36.
In another report released on August 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $26.00 price target.